Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

A Study of IBI355 in Participants With Moderate-to-Severe Sjögren's Disease

18 de septiembre de 2026 actualizado por: Innovent Biologics (Suzhou) Co. Ltd.

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of IBI355 in Participants With Moderate-to-Severe Sjögren's Disease

This is a Phase II, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of IBI355 in participants with moderate-to-severe Sj?gren's disease (SjD).

Descripción general del estudio

Descripción detallada

This study is a randomized, double-blind, placebo-controlled Phase II study in participants with moderate-to-severe Sjögren's disease. Eligible participants will be randomized to receive IBI355 or placebo during the double-blind treatment period.

The study will evaluate the efficacy of IBI355 in reducing systemic disease activity and improving patient-reported symptoms and disease-related functional outcomes. Safety and tolerability will be assessed throughout the study. Pharmacokinetic, immunogenicity, pharmacodynamic, and other relevant clinical assessments will also be performed as specified in the protocol.

The results of this study are intended to characterize the efficacy and safety profile of IBI355 in participants with Sjögren's disease and to support its further clinical development.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

198

Fase

  • Fase 2

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Ubicaciones de estudio

    • Anhui
      • Hefei, Anhui, Porcelana, 230001
        • The First Affiliated Hospital of University of Science and Technology of China
        • Investigador principal:
          • Xiaomei Li, M.D.
        • Contacto:
        • Sub-Investigador:
          • Zhen Tan, M.D.

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 75 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Age ≥18 and ≤75 years.
  • Diagnosis of Sjögren's syndrome per 2016 ACR/EULAR classification criteria.
  • Duration of Sjögren's syndrome diagnosis ≤7.5 years.
  • Serum anti-Ro/SSA (Ro60 and/or Ro52) positive.
  • Stimulated whole saliva flow rate ≥0.05 mL/min at screening.
  • Baseline ESSDAI score ≥5 in ≥1 of the following domains: systemic, lymphadenopathy, glandular, articular, cutaneous, renal, hematologic, biological.
  • Stable background therapy (hydroxychloroquine ≤400 mg/day, methotrexate ≤25 mg/week, or azathioprine ≤150 mg/day) for ≥12 weeks with stable dose ≥8 weeks prior to randomization.
  • Stable oral corticosteroid dose (≤10 mg/day prednisone equivalent) for ≥4 weeks prior to randomization.

Exclusion Criteria:

  • Known hypersensitivity to IBI355 or its excipients.
  • Pregnancy or breastfeeding.
  • Uncontrolled interstitial lung disease (ILD) associated with Sjögren's syndrome (e.g., FVC <70% predicted, ClinESSDAI pulmonary domain indicating severe activity, or NYHA Class III/IV dyspnea).
  • Active or untreated latent tuberculosis (IGRA-positive without ≥1 month prophylactic treatment).
  • Chronic hepatitis B (HBsAg+), hepatitis C (HCV RNA+), HIV, or syphilis.
  • Prior use of rituximab, other anti-CD20 agents, or other biologics targeting CD40/CD40L, BAFF/APRIL, or CTLA-4 within 6 months prior to randomization.
  • Use of JAK/TYK inhibitors within 8 weeks prior to randomization.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Doble

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Part A: IBI355 group

IBI355,IV,corresponding dose regimen according to study cohort( Part A) .

Matching placebo of IBI355, IV ,corresponding dose regimen according to study design

IBI355,IV,corresponding dose regimen according to study design

Experimental: Part B: Telitacicept 160 mg group

Participants received telitacicept 160 mg SC QW from Week 0 to Week 24. Follow-up through Week 36

Telitacicept 160 mg SC QW × 24 doses (Weeks 0-24).

Experimental: Part A: Placebo group(IBI355-matched)

Matching placebo of IBI355, IV ,corresponding dose regimen according to study design

Matching placebo of IBI355, IV ,corresponding dose regimen according to study design

IBI355,IV,corresponding dose regimen according to study design

Experimental: Part B: Placebo group (Telitacicept-matched)

Participants received matching placebo SC QW from Week 0 to Week 24. Follow-up through Week 36.

Matching placebo of Talitacicept ,SC QW × 24 doses.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change from Baseline in EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) Score at Week 24
Periodo de tiempo: Baseline and Week 24

The EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) is a physician-assessed index used to evaluate systemic disease activity in Sjögren's disease. The total score ranges from 0 to 123, with higher scores indicating greater systemic disease activity. A decrease from baseline indicates improvement.

Baseline and Week 24

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change from Baseline in ESSDAI Score at Weeks 12 and 48
Periodo de tiempo: Baseline to Weeks 12 and 48

The EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) is a physician-assessed index used to evaluate systemic disease activity in Sjögren's disease. The total score ranges from 0 to 123, with higher scores indicating greater systemic disease activity. A decrease from baseline indicates improvement.

Baseline to Weeks 12 and 48
Change from Baseline in EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) Score at Weeks 12, 24, and 48
Periodo de tiempo: Baseline to Weeks 12, 24, and 48

The EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) is a patient-reported measure assessing dryness, fatigue, and pain. Each domain is rated on a 0-to-10 numerical rating scale, and the total ESSPRI score is calculated as the mean of the three domain scores, ranging from 0 to 10. Higher scores indicate greater symptom severity. A decrease from baseline indicates improvement.

Baseline to Weeks 12, 24, and 48
Change from Baseline in Stimulated Salivary Flow (sSF) Rate at Weeks 12, 24, and 48
Periodo de tiempo: Baseline to Weeks 12, 24, and 48

Stimulated salivary flow rate will be measured according to the protocol-specified procedure. An increase from baseline indicates an improvement in stimulated salivary gland function.

Baseline to Weeks 12, 24, and 48
Change from Baseline in Schirmer Test at Week 48
Periodo de tiempo: Baseline to Week 48

The Schirmer test is used to assess tear production and is reported as the length of wetting of the test strip over 5 minutes, measured in millimeters (mm/5 min). Higher values indicate greater tear production.

Baseline to Week 48
Change from Baseline in Sj?gren's Tool for Assessing Response (STAR) Score at Week 48
Periodo de tiempo: Baseline to Week 48

The Sj?gren's Tool for Assessing Response (STAR) is a composite assessment of treatment response in Sj?gren's disease incorporating systemic disease activity, patient-reported symptoms, and biological and glandular domains. Higher scores indicate a greater treatment response.

Baseline to Week 48
Change from Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score at Weeks 12, 24, and 48
Periodo de tiempo: Baseline to Weeks 12, 24, and 48

The FACIT-Fatigue scale is a 13-item patient-reported measure of fatigue. The total score ranges from 0 to 52, with higher scores indicating less fatigue and better functioning. An increase from baseline indicates improvement.

Baseline to Weeks 12, 24, and 48
Change from Baseline in EuroQol 5-Dimension 5-Level (EQ-5D-5L) Index Score at Weeks 12, 24, and 48
Periodo de tiempo: Baseline to Weeks 12, 24, and 48

The EQ-5D-5L is a standardized measure of health status assessing five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has five levels of severity. Responses are converted to an EQ-5D-5L index score using the prespecified value set, with higher index scores indicating better health status.

Baseline to Weeks 12, 24, and 48
Incidence of Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Periodo de tiempo: From the first dose of study intervention through Week 48

The number and percentage of participants experiencing treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) will be assessed throughout the study.

From the first dose of study intervention through Week 48

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

15 de octubre de 2026

Finalización primaria (Estimado)

1 de noviembre de 2027

Finalización del estudio (Estimado)

31 de octubre de 2028

Fechas de registro del estudio

Enviado por primera vez

13 de septiembre de 2026

Primero enviado que cumplió con los criterios de control de calidad

18 de septiembre de 2026

Publicado por primera vez (Actual)

23 de septiembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

23 de septiembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

18 de septiembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir